Hepatobiliary Cancers, Version 1.2017: Featured Updates to the NCCN Guidelines
Al B. Benson,Michael I. D’Angelica,Daniel E. Abbott,Thomas A. Abrams,Steven R. Alberts,Daniel Anaya Saenz,Chandrakanth Are,Daniel B. Brown,Daniel T. Chang,Anne M. Covey,William G. Hawkins,Renuka Iyer,Rojymon Jacob,Andrea Karachristos,R. Kate Kelley,Robin D. Kim,Manisha Palta,James O. Park,Vaibhav Sahai,Tracey E. Schefter,Carl Schmidt,Jason K. Sicklick,Gagandeep Singh,Davendra Sohal,Stacey Stein,G. Gary Tian,Jean Nicolas Vauthey,Alan P. Venook,Andrew X. Zhu,Karin G. Hoffmann,Susan Darlow +30 more
Reads0
Chats0
TLDR
The NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.Abstract:
The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.read more
Citations
More filters
Journal ArticleDOI
Liver Resection and Surgical Strategies for Management of Primary Liver Cancer.
Sonia T. Orcutt,Daniel A. Anaya +1 more
TL;DR: For both diseases, onco-surgical strategies including portal vein embolization and parenchymal-sparing resections have increased the number of patients eligible for curative liver resection by improving patient outcomes.
Journal ArticleDOI
Institutional decision to adopt Y90 as primary treatment for hepatocellular carcinoma informed by a 1,000-patient 15-year experience
Riad Salem,Ahmed Gabr,Ahsun Riaz,R. Mora,R. Ali,Michael Abecassis,Ryan Hickey,Laura Kulik,Daniel Ganger,Steven L. Flamm,Rohi Atassi,Bassel Atassi,Kent T. Sato,Al B. Benson,Mary F. Mulcahy,N. Abouchaleh,Ali Al Asadi,Kush R. Desai,Bartley Thornburg,Michael Vouche,Ali Habib,Juan Carlos Caicedo,Frank H. Miller,Vahid Yaghmai,Joseph Ralph Kallini,Samdeep K. Mouli,Robert J. Lewandowski +26 more
TL;DR: Based on the experience with 1,000 patients over 15 years, TARE is made a decision to adopt as the first‐line transarterial LRT for patients with HCC.
Journal ArticleDOI
Surgery for cholangiocarcinoma.
Umberto Cillo,Constantino Fondevila,Matteo Donadon,Enrico Gringeri,Federico Mocchegiani,Hans J. Schlitt,Jan N. M. IJzermans,Marco Vivarelli,Krzysztof Zieniewicz,Steven W.M. Olde Damink,Steven W.M. Olde Damink,Bas Groot Koerkamp +11 more
TL;DR: This review addresses several challenges in surgical management of cholangiocarcinoma, including the high post‐operative mortality that has decreased in very high volume Asian centres, but remains about 10% in many Western referral centres.
Journal ArticleDOI
Advances in the early diagnosis of hepatocellular carcinoma.
Weiyi Wang,Chao Wei +1 more
TL;DR: The progress made in HCC diagnostics is reviewed, with a focus on emerging imaging techniques and biomarkers for early disease diagnosis.
Journal ArticleDOI
Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma.
Ziyu Liu,Yan Lin,Jinyan Zhang,Yumei Zhang,Yongqiang Li,Zhihui Liu,Qian Li,Ming Luo,Rong Liang,Jiazhou Ye +9 more
TL;DR: Despite phase III trials for nivolumab and pembrolizumab, the primary endpoints of improved OS were not statistically significant, immune PD-1/PD-L1 checkpoint therapy remains to be further investigated.
References
More filters
Journal ArticleDOI
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
Elizabeth Eisenhauer,P. Therasse,Jan Bogaerts,Lawrence H. Schwartz,Daniel J. Sargent,Robert Ford,Janet Dancey,S. Arbuck,S. Gwyther,Margaret M. Mooney,Larry Rubinstein,Lalitha K. Shankar,Lori E. Dodd,Robert M. Kaplan,Denis Lacombe,Jaap Verweij +15 more
TL;DR: The revised RECIST includes a new imaging appendix with updated recommendations on the optimal anatomical assessment of lesions, and a section on detection of new lesions, including the interpretation of FDG-PET scan assessment is included.
Journal ArticleDOI
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Jordi Bruix,Morris Sherman,Josep M. Llovet,Michel Beaugrand,Riccardo Lencioni,Andrew K. Burroughs,Erik Christensen,Luigi Pagliaro,Massimo Colombo,Juan Rodés +9 more
Journal ArticleDOI
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
TL;DR: A group of experts developed a set of guidelines aimed at providing a common framework for the design of clinical trials in HCC and adapted the concept of viable tumor-tumoral tissue showing uptake in arterial phase of contrast-enhanced radiologic imaging techniques-to formally amend RECIST, referred to herein as the modified RECIST assessment (mRECIST).
Journal ArticleDOI
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
Josep M. Llovet,Maria Isabel Real,Xavier Montaña,Ramon Planas,Susana Coll,John J. Aponte,Carmen Ayuso,Margarita Sala,Jordi Muchart,Ricard Solà,Joan Rodés,Jordi Bruix +11 more
TL;DR: Chemoembolisation improved survival of stringently selected patients with unresectable hepatocellular carcinoma and was associated with a significantly lower rate of portal-vein invasion than conservative treatment.
Journal ArticleDOI
Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome
Giulio Marchesini,Elisabetta Bugianesi,Gabriele Forlani,Fernanda Cerrelli,Marco Lenzi,R. Manini,S. Natale,Ester Vanni,Nicola Villanova,Nazario Melchionda,Mario Rizzetto +10 more
TL;DR: The presence of multiple metabolic disorders is associated with a potentially progressive, severe liver disease and the increasing prevalence of obesity, coupled with diabetes, dyslipidemia, hypertension, and ultimately the metabolic syndrome puts a very large population at risk of forthcoming liver failure in the next decades.
Related Papers (5)
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more